Vera Maslova

EP enthusiast, University Hospital Kiel, Germany | Senior Reviewer @EHJCREiC | #EHRA_ESC E-comm committee | 🔴 Nucleus @youngDGK

[Vera Maslova @veramasloo]

#EPeeps how can we recognize,if the potential in LSPV is LAA farfield,or a signal from PV?Look at the separation of potentials during distal CS pacing!
@evgeny_lyan @ThomasDemming #fellowsfirst #CardioTwitter #FOAMed

[Vera Maslova @veramasloo]

Check out our #EP_Kiel published case report in @HRS_CaseReports on RA- to LV Access Guided by CT merged with 3D Mapping for VT Ablation in patient with mechanical aortic and mitral valves!

[Heart Rhythm Case Reports @HRS_CaseReports]

Right Atrium-to-Left Ventricle Access Guided by Computed Tomography Merged with 3D Mapping for VT Ablation in a Patient with Mechanical Aortic and Mitral Valves
@veramasloo @evgeny_lyan @CKuehl2015
https://t.co/8W1TxoTbyY

[Heart Rhythm Case Reports @HRS_CaseReports]

Right Atrium-to-Left Ventricle Access Guided by Computed Tomography Merged with 3D Mapping for VT Ablation in a Patient with Mechanical Aortic and Mitral Valves
@veramasloo @evgeny_lyan @CKuehl2015
https://t.co/8W1TxoTbyY

[Vera Maslova @veramasloo]

@JICE_EP @ftrae Interesting! @ftrae why potato? And not for example porcine?

[Vera Maslova @veramasloo]

@syamkumarmd Could be PJRT? Pat is young, incessant Tachy, long RP

[Vera Maslova @veramasloo]

@NikhilShahMD do you know, if the manuscript ia already published? can not find it

[Chris Kowalewski MD @C_KowalewskiMD]

Bipolar ablation for VT does not have to be on the septum…
@veramasloo ablating between endo and epicardium.
@HRS

[Chris Kowalewski MD @C_KowalewskiMD]

Always wondered how to map VT by stimulation?
Very nice example by @ivroca on s1s2s3.
Sucessively shorter coupled stimuly that lead to slower conduction and uncover functional block. See how both the absolute and relative delay increase depending on substrate.

[Sandeep Gautam @gautamsand]

📢LBCT ASCEND CSP #HRS2026 (+ Simultaneous pub @hrs_journal) @rdschaller @Drdevignair @pvijayaraman1 @HRSonline #SciComms
*⃣Another step toward true physiologic ICD therapy:
👉 A purpose-built, stylet-driven CSP ICD lead by Abbott for LBBAP
➡️Prospective, global IDE trial (n=205)
• Implant success: 98.5%
• LBBAP achieved: 99% (86% true/likely LBB capture)
• Primary effectiveness: 94.6% (exceeded 80% goal)
• Stable thresholds + sensing at 3 months
➡️Defibrillation performance (critical for ICD adoption):
• 100% DFT success
• 92.5% terminated with single 20J shock
👉 No compromise in shock efficacy despite septal lead position
➡️Safety signal:
• 97.5% complication-free at 3 months
• Events included:
– 2 lead dislodgements
– 1 septal perforation (LV entry, required lead removal)
– 1 helix mechanical failure
– 1 drop in R-wave amplitude
➡️Clinical Implication:
✴️This is the first dedicated, stylet-driven bipolar ICD lead engineered for CSP, specifically modified for septal/LBBA implantation
✴️Potential to enable physiologic ICD or LOT-CRT
⚠️ Caveats:
• Single-arm (no RV lead comparator)
• Short follow-up (3 months)
• Operator-dependent CSP success
• Unknown long-term durability, extractability, and TR impact
https://t.co/tCZY2On3ML

[Chris Kowalewski MD @C_KowalewskiMD]

Happy to be invited to discuss the Proton late breakers with Dr. Lloyd and @KarimBenali42.
It’s different to photons as it delivers right to the spot. Looking forward to more proton data.

[Vera Maslova @veramasloo]

#LBCT #HRS2026 @HRSonline
Proton beam radio ablation for refractoryVT by @konsiont
➡️first in human,prospective,non-randomised
➡️scar-mediated VT,all had previous Ablation+AAD fail
👨‍🦱7pts,4 NICM,1ICM,2mixed
❗️FU 17 mo, 79%reduction in VTevents
🧷No SAEs; 5of 7died/Transplant

[Vera Maslova @veramasloo]

#LBCT #HRS2026 @HRSonline
Early US experience of VT ablation with Sphere-9 @Osama_Dasa @Dr_Santangeli
👨‍🦱59pts (VT n=50,PVC n=9)
🎯RFA first line,PFA adjunctive in dense scar, epi-PFA only, no PFA in border zone
✅VT-non ind. 78%; VT free at 6 mo 70%
❗️complications 5%

[Vera Maslova @veramasloo]

#LBCT on #HRS2026 @HRSonline by Saurabh Kumar
CAAD-VT Trial: ablation vs AAD in ICM&NICM
🌎Multicenter,randomized,9centers in Australia
🔚endpoint: free from VT, VT storm,death
👨‍🦱100pts,48%ICM,52%NICM
on FU 36mo, ablation: REDUCED RISK OF COMPOSITE ENDPOINT vs AAD (51%vs71%)

[Vera Maslova @veramasloo]

#LBCT on #HRS2026!
FULCRUM-VT trial:Ultra-low temperature VT ablation by @atulverma_md
🌎209 pts, 19 sites,2/3 ICM,1/3NICM
🧷safety endpoint:2.4%
🎯acute effectiveness 98%
✅chronic effectiveness:59%freedom from VT/AAD escalation, no difference ICMvs NICM
⬇️of VT burden,VTshocks

[Pasquale Santangeli @Dr_Santangeli]

Congrats to @omwazni and coinvestigators for this amazing achievement @CleClinicHVTI

[Vera Maslova @veramasloo]

#LBCT AVANT-GUARD on #HRS2026
PFA vs AAD for persistent AF as first line therapy,prospective randomized trial by Oussama Wazni
👥310 pts randomized
❗️PFA was superior in freedom from AF compared to AAD(56% vs 30.1%, p<0.01)
➡️Serious adverse events were similar
@HRSonline

[Vera Maslova @veramasloo]

🚨 High-impact science at #HRS2026

@RolandTilz presents #TiFFANY: fatal adverse events after AF abl (MAUDE + EMBOL-AF)

⚡PFA →↑ mortality (~3.7× vs RF)
🩸Tamponade → #1cause of death
🔥❄️ Thermal→oesophageal complications (#2)
⚡ PFA → arrhythmic deaths (#2)
@HRSonline

[Vera Maslova @veramasloo]

#HRS2026 Long term effect of PFA on coronary arteries: a serial OCT Study
35pts,PFA for CTI with pentaspline catheter

➡️PFA CTI- mild decrease in RCA lumen, no progress between 3 and 19 mo,even in patients with atherosclerosis

➡️Upon 25mo FU none developed coronary ischemia

[EHRAPresident @EHRAPresident]

🌍 Introducing a brand-new #EHRA_ESC format: #EHRAroundTheGlobe

We're hitting the road — traveling to our sister society meetings to bring you the most important scientific breakthroughs in heart rhythm, straight from the source

🇺🇸 First stop: #HRS2026 in Chicago
@simovicst sat down with @purerfellner to break down the highlights from the #HRS2026 this year.

What's making waves at #HRS2026? Find out 👇

[Omar Baqal, MD @omarjavedbaqal]

Good morning HRS! Check out our reflections on Day 2 and what we are excited about for Day 3. ⚡

https://t.co/UqFfGQCR5H

#HRS2026 @HRSonline
@gautamsand @np_varghese @kcole_12 @omarjavedbaqal
@nat_ved @simovicst @veramasloo @arbelo_e @bogdienache
@Nishaki1 @netta_doc

[Vera Maslova @veramasloo]

ASCEND CSP Trial on #HRS2026 @rdschaller
ICD Lead for CSP , first prospective IDE trial
👥205 patients 202 successful implants 🎯99%LBBAP
➡️97.5 free from lead-related SADEs
➡️DFT success 100%
❗️Implantation was feasible and met the prespecified safety and efficacy endpoints❗️